Assessing FNP-223 for slowing progression of Progressive Supranuclear Palsy
Official title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)
Run by Ferrer Internacional S.A. · NCT06355531 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if a new drug called FNP-223 can help slow down the progression of Progressive Supranuclear Palsy in people living with the condition.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | Ferrer Internacional S.A. Industry-sponsored |
| Locations | 42 sites (Carlsbad, California and 41 other locations) |
| Trial ID | NCT06355531 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are males and females aged 50 to 80 with a diagnosis of possible or probable PSP-RS and specific clinical features.
✕Probably not a fit
Patients with advanced PSP symptoms or those residing in skilled nursing facilities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial evaluates the efficacy and safety of FNP-223 in slowing the progression of Progressive Supranuclear Palsy (PSP) over a 52-week period. Participants will be assessed using the PSP Rating Scale to measure changes in their condition. The study includes both an active treatment group receiving FNP-223 and a placebo group for comparison. The aim is to determine if FNP-223 can effectively slow disease progression in individuals diagnosed with PSP.
Why it matters
Potential benefit: If successful, this treatment could significantly slow the progression of PSP, improving quality of life for patients.
How similar studies have gone: While there have been studies on PSP treatments, the specific approach with FNP-223 is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female participants aged 50 to 80 years, inclusive, at the time of informed consent. * Diagnosis of possible or probable PSP of the Richardson's Syndrome (PSP-RS) phenotypes according to the Movement Disorders Society's Progressive Supranuclear Palsy (MDS PSP) clinical features criteria. At least 1 (either 1 or both) of the following 2 items must be met: 1. Vertical supranuclear gaze palsy. 2. Slowing of vertical saccades AND postural instability with falls within the first 3 years of PSP symptoms. * Presence of PSP symptoms within ≤3 years prior to screening. * MoCA score ≥23 * Full 28-item PSPRS score ≤40. * Able to ambulate independently or with minimal assistance defined as the ability to take at least 10 steps (stabilization of 1 arm \[ie, use of cane\]). * Body weight range ≥43 kg/95 lbs to ≤120 kg/265 lbs. * Reside outside a skilled nursing facility or dementia care facility, except for participants residing in an assisted living facility. * Has a caregiver or study partner who will accompany them to the study visits. The caregiver or study partner must be a person who has frequent contact (at least 7 hours per week at 1 time or in different days) with the participant and is able to provide information about the participant's medication and overall condition. Prior to the conduct of any study procedures, the caregiver or study partner must be willing to sign the independent ethics committee (IEC)/institutional review board (IRB) approved informed consent. Exclusion Criteria: Non-PSP- RS Movement Disorders or other central nervous system (CNS) Diseases * Score of 3 on any functional domain in the PSP-CDS. * Participants with known PSP genetic mutation (based on familiar or clinical history). * Evidence of other neurological disorder that could explain signs of PSP (eg, Parkinson's disease, Alzheimer disease, etc.). * Brain magnetic resonance imaging (MRI) within 1 year of screening consistent with: * Primary degenerative diseases other than PSP. Procedures * For the optional substudy only: Contraindication or refusal to undergo 2 lumbar punctures for obtaining CSF. * Contraindication or inability to tolerate MRI for screening MRI and volumetric brain MRI assessments throughout the substudy.
Where it's running
-
The Neurology Center of Southern California - Carlsbad
Carlsbad, California, United States Recruiting -
UCSF Weill Institute for Neurosciences
San Francisco, California, United States Recruiting -
Rocky Mountain Movement Disorders Center
Denver, Colorado, United States Recruiting -
University of Miami Miller School of Medicine
Miami, Florida, United States Recruiting -
Augusta University
Augusta, Georgia, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Show 36 more locations
-
Quest Research Institute
Farmington Hills, Michigan, United States Recruiting -
Robert & John M. Bendheim Parkinson and Movement Disorders Center at Mount Sinai
New York, New York, United States Recruiting -
Columbia University Irving Medical Center
New York, New York, United States Recruiting -
Duke Neurology
Durham, North Carolina, United States Recruiting -
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting -
Central Texas Neurology Consultants
Round Rock, Texas, United States Recruiting -
Groupe Hospitalier Pellegrin
Bordeaux, France Recruiting -
Hôpital de la Timone
Marseille, France Recruiting -
L'Hôpital Universitaire Carémeau
Nîmes, France Recruiting -
Hôpital Universitaire Pitié Salpêtrière
Paris, France Recruiting -
Hôpital Pierre-Paul Riquet
Toulouse, France Recruiting -
Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
Beelitz, Germany Recruiting -
Universitätsklinikum Düsseldorf
Düsseldorf, Germany Recruiting -
Universitätsklinikum Leipzig
Leipzig, Germany Recruiting -
Ludwig-Maximilians-Universität München (LMU)
Munich, Germany Recruiting -
Pécsi Tudományegyetem Általános Orvostudományi Kar
Pécs, Hungary Recruiting -
IRCCS Istituto Delle Scienze Neurologiche di Bologna
Bologna, Italy Recruiting -
Azienda Ospedale Università di Padova
Padova, Italy Recruiting -
Azienda Ospedaliero-Universitaria Pisana
Pisa, Italy Recruiting -
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana
Roma, Italy Recruiting -
Azienda Ospedaliera Universitaria San Giovanni di Dio Ruggi d'Aragona
Salerno, Italy Recruiting -
Neurologia Śląska Centrum Medyczne
Katowice, Poland Recruiting -
Mazowiecki Szpital Bródnowski w Warszawie
Warsaw, Poland Recruiting -
Hospital de Braga
Braga, Portugal Recruiting -
Campus Neurológico Senior - Torres Vedras
Torres Vedras, Portugal Recruiting -
Complejo Hospitalario Universitario A Coruña
A Coruña, Spain Recruiting -
Hospital Germans Trias i Pujol
Badalona, Spain Recruiting -
Hospital Universitario Cruces
Barakaldo, Spain Recruiting -
Hospital Clínic de Barcelona
Barcelona, Spain Recruiting -
Hospital Universitario Ramón y Cajal
Madrid, Spain Recruiting -
Hospital Universitario 12 de Octubre
Madrid, Spain Recruiting -
Hospital Universitario de Navarra
Pamplona, Spain Recruiting -
Hospital Universitario Virgen del Rocío
Sevilla, Spain Recruiting -
Hospital Universitari i Politècnic La Fe
Valencia, Spain Recruiting -
University of Cambridge
Cambridge, United Kingdom Recruiting -
University Hospital Southampton
Southampton, United Kingdom Recruiting
Study contacts
- Study coordinator: Ferrer MedInfo
- Email: medinfo@ferrer.com
- Phone: +34 609 850 565
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Wellness program for PSP and CBD: a virtual multimodal lifestyle approach
This study tests a virtual 8-week program combining chair yoga, voice strengthening, and peer support to see if it improves emotional wellbeing and quality of life for adults with PSP or CBD and whether it eases caregiver burden.
-
Personalized magnetic brain stimulation for parkinsonian disorders
This study will try personalized repetitive transcranial magnetic stimulation (rTMS) to see if it eases motor and non-motor symptoms in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy.
-
tDCS to improve walking and movement in PSP, corticobasal syndrome, and Parkinson's disease
The study will try applying gentle brain stimulation (tDCS) during walking practice to see if it improves gait, speech, eye movements, and hand dexterity in people with PSP, corticobasal syndrome, or Parkinson's disease.
-
ARO-MAPT-SC in healthy adults and people with early Alzheimer's disease
This trial will test whether ARO-MAPT-SC is safe, tolerable, and produces the expected drug levels and biomarker effects in healthy adults and people with early Alzheimer's disease.
-
Genetic program for Progressive Supranuclear Palsy and related conditions
This study is collecting DNA from adults with Progressive Supranuclear Palsy and similar conditions to see how genetics might help improve diagnosis and care for patients.
-
Examining health services and quality of life in patients with atypical Parkinsonian syndromes
This study looks at how people with atypical Parkinsonian syndromes, like progressive supranuclear palsy and multiple system atrophy, use health services and how their quality of life is affected by having access to specialist clinics and support services.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.